At 21.8% CAGR, the North America Organoids Market is Projected to be Worth US$ 6,574.44 Million by 2031, Says Business Market Insights

According to Business Market Insights research, the North America organoids market was valued at US$ 1,357.19 million in 2023 and is expected to reach US$ 6,574.44 million by 2031, registering a CAGR of 21.8% from 2023 to 2031. Increasing demand for tumor modeling and biobanking and biobanking and combination of organoids and organ-on-a-chip are among the critical factors attributed to the North America organoids market expansion.

Organoids are microscopic and self-organized 3D structures derived in vitro from stem cells. They exhibit various structural and functional characteristics of their vivo counterpart organs. This multipurpose technology has led to numerous new human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a variety of cancers. Alternatively, CRISPR-based gene modification allows the creation of cancer organoid models by introducing any combination of cancer gene modifications to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, generate a cancer microenvironment model that enables immune-oncology applications. Recent studies emphasize the significant role of organoids in personalized medicine approaches. Continuous advancements in organoid technology have enabled tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Organoids have been generated from breast, bladder, colon, prostate, pancreas, and liver cancer in humans over the past few decades. Studies involving these models help provide a clear overview of these malignancies. Tumoroid lines being introduced in vitro are opening new avenues for a range of downstream applications such as drug discovery and development and cancer research. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines.

Recent research and development activities have indicated that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large group of patients. As organoids can be easily derived and expanded from single cancer cells, organoids are increasingly being introduced into applications to mimic intratumor differentiation in culture. Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, the increasing demand for tumor modeling and biobanking fuels the organoids market growth.

On the contrary, dearth of skilled professionals hampers the growth of North America organoids market.

Based on type, the North America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.2% share of the North America organoids market in 2023, amassing US$ 315.02 million. It is projected to garner US$ 1,498.21 million by 2031 to expand at 21.5% CAGR during 2023–2031.

Based on application, the North America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.5% share of the North America organoids market in 2023, amassing US$ 400.66 million. It is projected to garner US$ 2,031.75 million by 2031 to expand at 22.5% CAGR during 2023–2031.

Based on source, the North America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.9% share of the North America organoids market in 2023, amassing US$ 989.94 million. It is projected to garner US$ 4,945.75 million by 2031 to expand at 22.3% CAGR during 2023–2031.

Based on offering, the North America organoids market is segmented into instruments, consumables, and services. The consumables segment held 54.9% share of the North America organoids market in 2023, amassing US$ 745.71 million. It is projected to garner US$ 3,617.59 million by 2031 to expand at 21.8% CAGR during 2023–2031. The instruments segment is further subsegmented into devices and equipment. The consumables segment is further subsegmented into sensors and others.

Based on method, the North America organoids market is segmented into micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion, and others. The hanging drop segment held 43.3% share of the North America organoids market in 2023, amassing US$ 587.90 million. It is projected to garner US$ 2,769.35 million by 2031 to expand at 21.4% CAGR during 2023–2031.

Based on country, the North America organoids market is segmented into the US, Canada, and Mexico. The US held 80.1% share of North America organoids market in 2023, amassing US$ 1,087.67 million. It is projected to garner US$ 5,345.49 million by 2031 to expand at 22.0% CAGR during 2023–2031.

Key players operating in the organoids market are STEMCELL Technologies Inc; Molecular Devices, LLC.; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA; InSphero; ACRO Biosystems; Bio-Techne Corp; SUN bioscience SA; ORGANOID SCIENCES Co., Ltd.; Crown Bioscience Inc; Sartorius AG; 3D Biotek LLC; Prellis Biologics Inc.; 3Dnamics Inc.; and Cellesce Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com